Antimicrobial Resistance Cost in Two Ghanaian Hospitals

By Staff Writer

January 8, 2024

Antimicrobial Resistance Costs: A Burden on Healthcare Providers

Antimicrobial resistance (AMR) and antimicrobial resistance costs are a global challenge with significant implications for healthcare providers. A recent study conducted in two public tertiary hospitals in Ghana, a lower-middle-income setting, quantified the healthcare provider costs (HPCs) due to AMR using both aggregated ingredient costing and step-down costing approaches. The results reveal that AMR patients demand more time and resources from healthcare providers than patients infected with susceptible bacteria or uninfected patients.

The Direct Impact of AMR on Hospitals

The study found that if AMR could be avoided, the extra 5 bed days allocated for treating an estimated 740 AMR patients annually at both hospitals would free up 3700 bed days, allowing for the admission of an additional 451 patients. Moreover, doctors spend an extra 7 hours at Hospital 1 and 3 hours at Hospital 2 caring for each AMR patient admitted to the hospital within a 30-day data collection period.

The Cost of AMR

The research also highlighted the variation in costs due to AMR causative pathogens. For instance, treating each patient with MRSA bloodstream infections at Hospital 1 was approximately 33% higher than treating K. pneumoniae and 16% higher than E. coli bloodstream infections resistant to 3GC. The provider cost of treating AMR was highest for the medical emergency unit due to its limited capacity to treat patients with severe and emergency health conditions compared to the general medical unit.

Mitigating AMR: A Matter of Urgency

The findings underscore the urgent need for healthcare providers and policymakers to focus on AMR mitigation measures. Such measures may include general infection prevention and control, effective antibiotic regulation, and adherence to WHO’s access, watch and reserve (AWaRe) recommendation for antibiotic prescription and therapy. The study also advocates for demand-driven strategies, such as point-of-care education regarding antibiotic use and resistance’s health and economic implications, and supply-driven interventions like hospital-wide antibiotic restriction policy implementation.

In conclusion, AMR imposes significant costs on healthcare providers, particularly in lower-middle-income settings. These costs can be avoided through a myriad of infection prevention and control strategies, thus making a strong case for investment in AMR mitigation strategies.

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.